Characterization of novel kainic acid analogs as inhibitors of select microglial functions

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) involves amyloid plaques, neurofibrillary tangles, and chronic neuroinflammation driven by microglia.
• Dysregulated microglial activation contributes to neuronal death in AD.
• Modulating microglial immune functions is a therapeutic strategy for neurodegenerative diseases.

Purpose of the Study:

• To synthesize and evaluate novel kainic acid analogs (KAAs) for their ability to modify microglial immune functions.
• To investigate the potential of KAAs as therapeutic agents for neuroinflammation and neurodegeneration in AD.

Main Methods:

• Synthesis of six novel kainic acid analogs (KAAs).
• Testing KAAs on three microglial cell models to assess effects on immune functions.
• Assessing inhibition of cytotoxins, monocyte chemoattractant protein (MCP)-1, reactive oxygen species, and nitric oxide (NO) secretion.
• Investigating potential targets, including aldose reductase (AR), using AR inhibitors.

Main Results:

• Four out of six KAAs significantly inhibited secretion of cytotoxins, MCP-1, reactive oxygen species, and NO in immune-stimulated microglia-like cells at low micromolar concentrations.
• The observed effects of KAAs were distinct from kainic acid (KA), suggesting non-KA receptor mediated mechanisms.
• Aldose reductase (AR) was identified as a potential target, with an AR inhibitor abolishing the inhibitory effects of two KAAs on NO secretion.

Conclusions:

• The novel KAAs demonstrate potent inhibitory effects on pro-inflammatory and cytotoxic microglial functions.
• These findings suggest that KAAs hold promise for further investigation in AD animal models to mitigate neuroinflammation and neurodegeneration.
• Targeting aldose reductase may be a mechanism underlying the beneficial effects of these novel compounds.